NASDAQ · ACLX
Healthcare · Biotechnology
$115.07
Up+$0.02 (+0.02%)
Updated Sep 11, 2026, 3:32 AM
SID Score
5.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ACLX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ACLX.
ACLX research
Company profile and research snapshot.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 26, 2026 | Guggenheim | Neutral | — |
| Feb 24, 2026 | Evercore ISI Group | In-Line | — |
| Feb 24, 2026 | Truist Securities | Hold | — |
| Feb 24, 2026 | Leerink Partners | Market Perform | — |
| Feb 24, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
Finnhub · Apr 28, 2026
Gilead Sciences, Inc. entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR...
Finnhub · Apr 27, 2026
Arcellx, Inc. dropped from S&P TMI Index...
Finnhub · Apr 27, 2026
Arcellx, Inc. dropped from S&P Biotechnology Select Industry Index...
Finnhub · Apr 27, 2026
Arcellx, Inc. dropped from S&P Global BMI Index...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACLX.
